On Invalid Date, Sonnet Biotherapeutics Holdings (NASDAQ: SONN) reported Q4 2023 earnings per share (EPS) of -$0.31, up 98.24% year over year. Total Sonnet Biotherapeutics Holdings earnings for the quarter were -$1.17 million. In the same quarter last year, Sonnet Biotherapeutics Holdings's earnings per share (EPS) was -$17.62.
As of Q1 2024, Sonnet Biotherapeutics Holdings's earnings has grown year over year. Sonnet Biotherapeutics Holdings's earnings in the past year totalled -$14.46 million.
What is SONN's earnings date?
Sonnet Biotherapeutics Holdings's earnings date is Invalid Date. Add SONN to your watchlist to be reminded of SONN's next earnings announcement.
What was SONN's revenue last quarter?
On Invalid Date, Sonnet Biotherapeutics Holdings (NASDAQ: SONN) reported Q4 2023 revenue of $18.63 thousand up 50% year over year. In the same quarter last year, Sonnet Biotherapeutics Holdings's revenue was $37.26 thousand.
What was SONN's revenue growth in the past year?
As of Q1 2024, Sonnet Biotherapeutics Holdings's revenue has grown -49.81% year over year. This is 219.11 percentage points lower than the US Biotechnology industry revenue growth rate of 169.3%. Sonnet Biotherapeutics Holdings's revenue in the past year totalled $129.18 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.